Research programme: small-molecule compounds - CytoCure
Latest Information Update: 02 Aug 2016
At a glance
- Originator CytoCure
- Class Antineoplastics; Small molecules
- Mechanism of Action Antigen stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Malignant melanoma
Most Recent Events
- 02 Aug 2016 Early research in Malignant melanoma (Combination therapy) in USA (unspecified route)